Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?
Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival ben...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/898931 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690968814518272 |
|---|---|
| author | Joanne Chiu Thomas Yau |
| author_facet | Joanne Chiu Thomas Yau |
| author_sort | Joanne Chiu |
| collection | DOAJ |
| description | Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival benefit. However, there were only marginal benefits in people with good performance status. Recently, the combination regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was found to achieve unprecedented survival benefit and has become the preferred option for patients with good clinical conditions. On the other hand, many biological agents have been combined with GEM, but only erlotinib was found to derive statistically significant survival advantage. However, the effect was too small to be appreciated clinically. The effort in development of targeted therapy in APC continues. This paper summarized key findings in the development of chemotherapy and targeted therapy for APC patients and discussed future directions in management. |
| format | Article |
| id | doaj-art-eaeba942d773432691ac08a53d16cd1a |
| institution | DOAJ |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-eaeba942d773432691ac08a53d16cd1a2025-08-20T03:21:10ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/898931898931Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?Joanne Chiu0Thomas Yau1University Department of Medicine, Queen Mary Hospital, Hong KongUniversity Department of Medicine, Queen Mary Hospital, Hong KongDevelopment of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival benefit. However, there were only marginal benefits in people with good performance status. Recently, the combination regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was found to achieve unprecedented survival benefit and has become the preferred option for patients with good clinical conditions. On the other hand, many biological agents have been combined with GEM, but only erlotinib was found to derive statistically significant survival advantage. However, the effect was too small to be appreciated clinically. The effort in development of targeted therapy in APC continues. This paper summarized key findings in the development of chemotherapy and targeted therapy for APC patients and discussed future directions in management.http://dx.doi.org/10.1155/2012/898931 |
| spellingShingle | Joanne Chiu Thomas Yau Metastatic Pancreatic Cancer: Are We Making Progress in Treatment? Gastroenterology Research and Practice |
| title | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment? |
| title_full | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment? |
| title_fullStr | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment? |
| title_full_unstemmed | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment? |
| title_short | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment? |
| title_sort | metastatic pancreatic cancer are we making progress in treatment |
| url | http://dx.doi.org/10.1155/2012/898931 |
| work_keys_str_mv | AT joannechiu metastaticpancreaticcancerarewemakingprogressintreatment AT thomasyau metastaticpancreaticcancerarewemakingprogressintreatment |